In this Huffington Post opinion piece, Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, examines the need for continued attention and funding for additional research for an AIDS vaccine, highlighting advancements presented at the AIDS Vaccine 2011 conference in Bangkok, Thailand, earlier this month. He writes, “We don’t yet have a blueprint for an effective vaccine to roll-out. But, as presented … in Bangkok, the complex success of the RV144 analysis, combined with a flurry of advances in understanding the development of broadly-neutralizing antibodies against HIV, show that the science of an AIDS vaccine is vibrant and vital. Now is exactly the time to maintain commitment.”

“We still have a long way to go, but with the right resources, the right leadership and with support from communities and the participation of trial volunteers, we can have an AIDS vaccine in our lifetime. And we can end this epidemic,” he concludes (9/28).